Article
Molecular spectrum of BRAF, NRAS and KRAS gene mutations in plasma cell dyscrasias: implication for MEK-ERK pathway activation.
Oncotarget - 15 Sept 2015
Lionetti Marta, Barbieri Marzia, Todoerti Katia, Agnelli Luca, Marzorati Simona, Fabris Sonia, Ciceri Gabriella, Galletti Serena, Milesi Giulia, Manzoni Martina, Mazzoni Mara, Greco Angela, Tonon Giovanni, Musto Pellegrino, Baldini Luca, Neri Antonino
Abstract excerpt
Multiple myeloma (MM) is a clinically and genetically heterogeneous plasma cell (PC) malignancy. Whole-exome sequencing has identified therapeutically targetable mutations such as those in the mitogen-activated protein kinase (MAPK) pathway, which are the most prevalent MM mutations. We used deep sequencing to screen 167 representative patients with PC dyscrasias [132 with MM, 24 with primary PC leukemia (pPCL)...
Topics
- Adult
- Aged
- Aged, 80 and over
- Apoptosis
- Cell Line, Tumor
- Exome
- Extracellular Signal-Regulated MAP Kinases
- Female
- GTP Phosphohydrolases
- Gene Expression Profiling